Several mutated oncogenes were found in our cohort of MM specimens including KRAS, NRAS, BRAF, and TP53. In the era of personalized medicine, the availability of rapid, high throughput genomic sequencing opens up the possibility of efficiently integrating genomic analysis into our clinical practice. This evidence concerns the gene NRAS and Miyoshi myopathy.